Caris Life Sciences, Inc. filings document financial results, governance matters, financing arrangements and material company events for an AI TechBio precision medicine business. Form 8-K disclosures report quarterly and annual operating results, molecular profiling services revenue, clinical therapy selection activity, and Regulation FD updates tied to company presentations and diagnostic-development programs.
The company’s SEC record also includes a definitive proxy statement covering annual meeting proposals, director elections and auditor ratification. Other material-event filings describe senior secured credit facilities with subsidiary guarantees, amendments to bylaws affecting shareholder derivative proceedings, and capital-structure terms relevant to Caris’ public-company reporting obligations.
Spetzler David Baxley reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. President David Baxley Spetzler received an award of 83,162 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and will vest in accordance with the applicable grant agreement. Following this compensation-related grant, he holds 543,939 shares of Common Stock directly.
Brille Brian J reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director and officer Brian J. Brille received a grant of 83,162 shares of Common Stock in the form of restricted stock units on March 6, 2026, at no cash cost, as compensation that will vest under the applicable grant agreement.
Following this grant, he directly holds 244,290 Common shares. In addition, a family trust holds 500,000 Common shares, with Brille reporting the position indirectly and disclaiming beneficial ownership except for his pecuniary interest.
Caris Life Sciences director and officer David D. Halbert reported an acquisition of 320,112 shares of Common Stock on March 6, 2026 as a restricted stock unit award that vests under its grant agreement. These shares were received at a stated price of $0.00 per share, bringing his directly held Common Stock to 2,615,245 shares after the transaction.
The filing also shows 121,025,002 shares of Common Stock held indirectly through several affiliated entities, including Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd., Caris Investment III Ltd., and Halbert Family Capital, LLC. Halbert has voting and investment power over these entity holdings but disclaims beneficial ownership beyond his pecuniary interest.
Caris Life Sciences, Inc. describes a precision oncology business built on comprehensive molecular profiling and artificial intelligence. The company focuses on tissue- and blood-based sequencing to guide cancer diagnosis, therapy selection, minimal residual disease tracking, and early detection.
Caris reports sequencing over 1,000,000 oncology cases as of December 31, 2025 and serving more than 6,000 ordering physicians. Its MI Profile tissue platform, Caris Assure blood platform, and planned whole genome solutions, including the Caris Detect early detection assay expected in 2026, generate large multi-modal datasets used for clinical care, biopharma partnerships, and internal drug discovery.
The company highlights FDA-approved MI Cancer Seek as a WES/WTS companion diagnostic, growing Medicare and commercial coverage for Caris Assure, extensive intellectual property, and a global research network. It also notes a substantial biopharma services and data-licensing business built on its clinico-genomic and imaging datasets.
Minor Lloyd reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Lloyd Minor reported receiving 2,492 shares of common stock on February 26, 2026. These shares were issued as equity in lieu of cash compensation for his 2025 board retainer fees, based on a ten-day average trading price. Following this award, his direct holdings increased to 18,621 shares of common stock.
Caris Life Sciences director Jeff L. Vacirca received a stock grant instead of cash board fees. On February 26, 2026, he acquired 2,492 shares of common stock at $20.06 per share as compensation for his 2025 board retainer, bringing his direct holdings to 18,621 shares.
Caris Life Sciences director David Paul Fredrickson acquired 2,492 shares of common stock as compensation. The shares were issued on February 26, 2026 in lieu of cash payment for his 2025 board retainer fees, valued at $20.06 per share.
After this stock award, his directly held stake increased to 18,621 common shares. The number of shares granted was calculated by dividing the cash retainer earned by the 10-day average volume-weighted average price per share through February 25, 2026.
HALBERT JON reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Jon Halbert received a grant of 2,492 shares of common stock as part of his 2025 board retainer, issued in stock instead of cash. The number of shares was based on the ten‑day average volume-weighted price through February 25, 2026 at $20.06 per share.
After this award, he directly holds 118,621 shares. An additional 625,000 shares are held indirectly through LAH Investments, Ltd., and 625,000 shares are held indirectly through the Jon and Linda Halbert Management Trust, following an in-kind distribution from Ke'Ohana Ventures, LLC. He disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
PHILLIPS T DANNY reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director T. Danny Phillips received a stock grant instead of cash for 2025 board retainer fees. He was awarded 3,739 shares of common stock at a reference price of $20.06 per share, bringing his direct holdings to 119,868 shares.
CASTLEMAN PETER M reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Peter M. Castleman received a grant of 5,509 shares of common stock on February 26, 2026, as compensation for his 2025 board retainer fees, instead of cash. The shares were valued at $20.06 each, based on a ten-day volume-weighted average price through February 25, 2026.
After this award, he directly holds 24,138 common shares. He also has indirect holdings reported as 100,000 shares through a family trust and 10,270,906 shares held by CLS-PF-SPE, LLC, an entity whose manager controls voting and investment power, while he disclaims beneficial ownership beyond his economic interest.